2013 Q2 Form 10-Q Financial Statement
#000110465913038074 Filed on May 07, 2013
Income Statement
| Concept | 2013 Q2 | 2013 Q1 |
|---|---|---|
| Revenue | $1.400M | $0.00 |
| YoY Change | -6.67% | -100.0% |
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $4.890M | $5.400M |
| YoY Change | -10.44% | -12.34% |
| % of Gross Profit | ||
| Research & Development | $19.39M | $20.32M |
| YoY Change | -7.32% | 13.47% |
| % of Gross Profit | ||
| Depreciation & Amortization | $630.0K | $669.0K |
| YoY Change | 3.28% | 21.2% |
| % of Gross Profit | ||
| Operating Expenses | $19.39M | $20.32M |
| YoY Change | -7.32% | 13.47% |
| Operating Profit | -$22.89M | -$25.71M |
| YoY Change | -8.03% | 10.3% |
| Interest Expense | $120.0K | $140.0K |
| YoY Change | -14.29% | |
| % of Operating Profit | ||
| Other Income/Expense, Net | ||
| YoY Change | ||
| Pretax Income | -$22.77M | -$25.57M |
| YoY Change | -7.96% | 10.36% |
| Income Tax | $0.00 | $0.00 |
| % Of Pretax Income | ||
| Net Earnings | -$22.77M | -$25.57M |
| YoY Change | -7.96% | 10.36% |
| Net Earnings / Revenue | -1626.43% | |
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$261.3K | -$293.4K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 87.14M shares | 87.14M shares |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2013 Q2 | 2013 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $251.6M | $272.5M |
| YoY Change | 24.19% | 22.01% |
| Cash & Equivalents | $21.90M | $34.16M |
| Short-Term Investments | $229.8M | $238.3M |
| Other Short-Term Assets | $2.900M | $3.000M |
| YoY Change | -21.62% | 7.14% |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | ||
| Other Receivables | ||
| Total Short-Term Assets | $254.6M | $275.4M |
| YoY Change | 23.35% | 21.82% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $5.500M | $5.833M |
| YoY Change | -9.84% | -1.2% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $1.600M | $1.701M |
| YoY Change | -15.79% | -11.96% |
| Total Long-Term Assets | $7.100M | $7.495M |
| YoY Change | -11.25% | -4.35% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $254.6M | $275.4M |
| Total Long-Term Assets | $7.100M | $7.495M |
| Total Assets | $261.7M | $282.9M |
| YoY Change | 22.06% | 20.94% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $2.100M | $2.138M |
| YoY Change | 10.53% | 11.24% |
| Accrued Expenses | $5.400M | $6.200M |
| YoY Change | -25.0% | 5.08% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $8.500M | $9.158M |
| YoY Change | -10.53% | 13.92% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | $8.200M | $91.00K |
| YoY Change | -9.89% | -18.75% |
| Total Long-Term Liabilities | $8.200M | $91.00K |
| YoY Change | -9.89% | -18.75% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $8.500M | $9.158M |
| Total Long-Term Liabilities | $8.200M | $91.00K |
| Total Liabilities | $16.60M | $9.249M |
| YoY Change | -10.75% | 13.47% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$785.8M | |
| YoY Change | 14.79% | |
| Common Stock | $1.051B | |
| YoY Change | 16.64% | |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $245.1M | $265.3M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $261.7M | $282.9M |
| YoY Change | 22.06% | 20.96% |
Cashflow Statement
| Concept | 2013 Q2 | 2013 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$22.77M | -$25.57M |
| YoY Change | -7.96% | 10.36% |
| Depreciation, Depletion And Amortization | $630.0K | $669.0K |
| YoY Change | 3.28% | 21.2% |
| Cash From Operating Activities | -$21.32M | -$25.11M |
| YoY Change | 2.8% | 7.91% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | -$250.0K | $676.0K |
| YoY Change | -69.51% | -57.05% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $8.460M | $26.46M |
| YoY Change | -65.87% | -4.68% |
| Cash From Investing Activities | $8.200M | $25.79M |
| YoY Change | -65.79% | -1.53% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 820.0K | 0.000 |
| YoY Change | -6.82% | -100.0% |
| NET CHANGE | ||
| Cash From Operating Activities | -21.32M | -25.11M |
| Cash From Investing Activities | 8.200M | 25.79M |
| Cash From Financing Activities | 820.0K | 0.000 |
| Net Change In Cash | -12.30M | 680.0K |
| YoY Change | -399.27% | -80.06% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$21.32M | -$25.11M |
| Capital Expenditures | -$250.0K | $676.0K |
| Free Cash Flow | -$21.07M | -$25.79M |
| YoY Change | 5.77% | 3.79% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2013Q1 | dei |
Document Type
DocumentType
|
10-Q | |
| CY2013Q1 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2013-03-31 | |
| CY2013Q1 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001034842 | |
| CY2013Q1 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2013Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | |
| CY2013Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
87140632 | shares |
| CY2013Q1 | dei |
Entity Registrant Name
EntityRegistrantName
|
RIGEL PHARMACEUTICALS INC | |
| CY2013Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2013Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2013 | |
| CY2013Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
| CY2013Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
34159000 | USD |
| CY2012Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
33484000 | USD |
| CY2013Q1 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
238291000 | USD |
| CY2012Q4 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
264757000 | USD |
| CY2013Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2955000 | USD |
| CY2012Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
4217000 | USD |
| CY2013Q1 | us-gaap |
Assets Current
AssetsCurrent
|
275405000 | USD |
| CY2012Q4 | us-gaap |
Assets Current
AssetsCurrent
|
302458000 | USD |
| CY2013Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
5833000 | USD |
| CY2012Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
5826000 | USD |
| CY2013Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
1701000 | USD |
| CY2012Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
1759000 | USD |
| CY2012Q4 | us-gaap |
Assets
Assets
|
310043000 | USD |
| CY2013Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
2138000 | USD |
| CY2012Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1697000 | USD |
| CY2013Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
3271000 | USD |
| CY2012Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
6775000 | USD |
| CY2013Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
873000 | USD |
| CY2012Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
942000 | USD |
| CY2013Q1 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
801000 | USD |
| CY2012Q4 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
666000 | USD |
| CY2012Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
USD | |
| CY2013Q1 | us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
127396000 | USD |
| CY2013Q1 | rigl |
Acrrued Research And Development Liability Current
AcrruedResearchAndDevelopmentLiabilityCurrent
|
2075000 | USD |
| CY2012Q4 | rigl |
Acrrued Research And Development Liability Current
AcrruedResearchAndDevelopmentLiabilityCurrent
|
2124000 | USD |
| CY2013Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
9158000 | USD |
| CY2012Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
12204000 | USD |
| CY2013Q1 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
8379000 | USD |
| CY2012Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
8647000 | USD |
| CY2013Q1 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
91000 | USD |
| CY2012Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
96000 | USD |
| CY2012Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2013Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2012Q1 | us-gaap |
Contracts Revenue
ContractsRevenue
|
750000 | USD |
| CY2012Q1 | us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
133685000 | USD |
| CY2013Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
USD | |
| CY2013Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
87000 | USD |
| CY2012Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
87000 | USD |
| CY2013Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
1050967000 | USD |
| CY2012Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
1049174000 | USD |
| CY2013Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
78000 | USD |
| CY2012Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
82000 | USD |
| CY2013Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-785821000 | USD |
| CY2012Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-760247000 | USD |
| CY2013Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
265311000 | USD |
| CY2012Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
289096000 | USD |
| CY2013Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
282939000 | USD |
| CY2012Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
310043000 | USD |
| CY2013Q1 | us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
20315000 | USD |
| CY2013Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5395000 | USD |
| CY2013Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
25710000 | USD |
| CY2012Q4 | rigl |
Cash Equivalents And Available For Sale Securities Amortized Cost
CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost
|
273972000 | USD |
| CY2012Q4 | rigl |
Cash Equivalents And Available For Sale Securities Gross Unrealized Gain
CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGain
|
135000 | USD |
| CY2012Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3098000 | USD |
| CY2013Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1793000 | USD |
| CY2013Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt 0.25in; TEXT-INDENT: -0.25in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt;" size="1">             </font></b> <b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt;" size="2">Nature of Operations</font></b></p> <p style="MARGIN: 0in 0in 0pt 0.25in; TEXT-INDENT: -0.25in; TEXT-ALIGN: center;" align="center"> </p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">We were incorporated in the state of Delaware on June 14, 1996. We are engaged in the discovery and development of novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders.</font></p> </div> | |
| CY2013Q1 | us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt 0.25in; TEXT-INDENT: -0.25in;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">2.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt;" size="1">             </font></b> <b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt;" size="2">Basis of Presentation</font></b></p> <p style="MARGIN: 0in 0in 0pt 0.25in; TEXT-INDENT: -0.25in;"> </p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Our accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP), for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Act of 1933, as amended (Securities Act). Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These unaudited condensed financial statements include only normal and recurring adjustments that we believe are necessary to fairly state our financial position and the results of our operations and cash flows. Interim-period results are not necessarily indicative of results of operations or cash flows for a full-year or any subsequent interim period. The balance sheet at December 31, 2012 has been derived from audited financial statements at that date, but does not include all disclosures required by U.S. GAAP for complete financial statements. Because all of the disclosures required by U.S. GAAP for complete financial statements are not included herein, these interim unaudited condensed financial statements and the notes accompanying them should be read in conjunction with our audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2012.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"> </p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from these estimates.</font></p> </div> | |
| CY2012Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.32 | |
| CY2013Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
87141000 | shares |
| CY2012Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
71422000 | shares |
| CY2013Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
15855000 | shares |
| CY2012Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
13922000 | shares |
| CY2013Q1 | us-gaap |
Availableforsale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses2
AvailableforsaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses2
|
0 | USD |
| CY2012Q4 | us-gaap |
Availableforsale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses2
AvailableforsaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses2
|
0 | USD |
| CY2013Q1 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2013Q1 | rigl |
Cash And Cash Equivalents And Available For Sale Securities Debt Securities Current
CashAndCashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesCurrent
|
272450000 | USD |
| CY2012Q4 | rigl |
Cash And Cash Equivalents And Available For Sale Securities Debt Securities Current
CashAndCashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesCurrent
|
298241000 | USD |
| CY2013Q1 | rigl |
Cash Equivalents And Available For Sale Securities Amortized Cost
CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost
|
263162000 | USD |
| CY2013Q1 | rigl |
Cash Equivalents And Available For Sale Securities Gross Unrealized Gain
CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGain
|
114000 | USD |
| CY2013Q1 | rigl |
Cash Equivalents And Available For Sale Securities Gross Unrealized Losses
CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLosses
|
36000 | USD |
| CY2013Q1 | rigl |
Cash Equivalents And Available For Sale Securities Debt Securities Unrealized Gain Loss Fair Value Disclosure
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesUnrealizedGainLossFairValueDisclosure
|
263240000 | USD |
| CY2012Q4 | rigl |
Cash Equivalents And Available For Sale Securities Gross Unrealized Losses
CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLosses
|
53000 | USD |
| CY2012Q4 | rigl |
Cash Equivalents And Available For Sale Securities Debt Securities Unrealized Gain Loss Fair Value Disclosure
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesUnrealizedGainLossFairValueDisclosure
|
274054000 | USD |
| CY2013Q1 | rigl |
Cash Equivalents And Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
CashEquivalentsAndAvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
|
208879000 | USD |
| CY2013Q1 | rigl |
Cash Equivalents And Available For Sale Securities Debt Maturities Rolling Year Two Fair Value
CashEquivalentsAndAvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoFairValue
|
54361000 | USD |
| CY2013Q1 | rigl |
Cash Equivalents And Available For Sale Securities Weighted Average Maturity Period
CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod
|
P214D | |
| CY2013Q1 | rigl |
Available For Sale Securities Debt Securities Current Stated Maturity Period May Be Greater Than This Period
AvailableForSaleSecuritiesDebtSecuritiesCurrentStatedMaturityPeriodMayBeGreaterThanThisPeriod
|
P1Y | |
| CY2013Q1 | us-gaap |
Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions
|
24 | item |
| CY2013Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.29 |
